Active Tumor-Targeted co-Delivery of Epigallocatechin Gallate and Doxorubicin in Nanoparticles for Combination Gastric Cancer Therapy.

MLA

Mi, Fwu-Long, et al. “Active Tumor-Targeted Co-Delivery of Epigallocatechin Gallate and Doxorubicin in Nanoparticles for Combination Gastric Cancer Therapy.” ACS Biomaterials Science & Engineering, vol. 4, no. 8, Aug. 2018, pp. 2847–59. EBSCOhost, https://doi.org/10.1021/acsbiomaterials.8b00242.

APA

Mi, F.-L., Wang, L.-F., Chu, P.-Y., Peng, S.-L., Feng, C.-L., Lai, Y.-J., Li, J.-N., & Lin, Y.-H. (2018). Active Tumor-Targeted co-Delivery of Epigallocatechin Gallate and Doxorubicin in Nanoparticles for Combination Gastric Cancer Therapy. ACS Biomaterials Science & Engineering, 4(8), 2847–2859. https://doi.org/10.1021/acsbiomaterials.8b00242

Chicago

Mi, Fwu-Long, Li-Fang Wang, Pei-Yi Chu, Shin-Lei Peng, Chun-Lung Feng, Ying-Jing Lai, Jia-Ni Li, and Yu-Hsin Lin. 2018. “Active Tumor-Targeted Co-Delivery of Epigallocatechin Gallate and Doxorubicin in Nanoparticles for Combination Gastric Cancer Therapy.” ACS Biomaterials Science & Engineering 4 (8): 2847–59. doi:10.1021/acsbiomaterials.8b00242.